Intellia stock plunges to 52-week low, hits $8.3 amid biotech rout

Intellia Therapeutics Inc . (NASDAQ:NTLA) stock has tumbled to a 52-week low, reaching a price level of just $8.3 as the biotech sector continues to face significant headwinds. According to InvestingPro data, the stock is currently trading below its Fair Value, with analyst price targets ranging from $9 to $106. The company, known for its pioneering work in CRISPR gene-editing technology, has seen its shares plummet over the past year, with a total return of -66.76%. While the company maintains a strong liquidity position with a current ratio of 5.77 and more cash than debt on its balance sheet, investors have been grappling with a mix of regulatory concerns, slower-than-expected clinical progress, and a challenging funding environment. The current price marks a critical juncture for Intellia, as stakeholders weigh the potential of its gene-editing pipeline against the backdrop of a risk-off sentiment in the broader biotech industry. Get deeper insights into NTLA’s financial health metrics and 12 additional ProTips with an InvestingPro subscription.

In other recent news, Intellia Therapeutics has secured a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational therapy, nexiguran ziclumeran (nex-z), targeting transthyretin amyloidosis with cardiomyopathy. This designation is expected to expedite the development and review process of nex-z, which has shown promising results in Phase 1 clinical trials. In parallel, Intellia has begun dosing patients in the global Phase 3 HAELO study for hereditary angioedema with its NTLA-2002 treatment, aiming for a potential launch by 2027. Despite these advancements, Intellia has faced several stock rating adjustments from analysts.

Goldman Sachs downgraded Intellia’s stock to Sell, setting a price target of $9, citing competition and concerns over the commercial viability of its treatments. JPMorgan also downgraded the stock to Neutral, reducing the price target to $13, due to the competitive landscape and the company’s strategic decisions. Meanwhile, Truist Securities lowered its price target to $50 but maintained a Buy rating, highlighting Intellia’s innovative platform despite competitive pressures. Citi analysts, however, slightly increased their price target to $14 while maintaining a Neutral stance, acknowledging Intellia’s commitment to clinical stage execution and its strategic financial planning to support operations into 2027. These developments reflect a mixed outlook from analysts on Intellia’s future prospects in a competitive gene-editing market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.